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The blood-brain barrier (BBB) is a critical structure that serves as the gatekeeper
between the central nervous system and the rest of the body. It is the responsibility
of the BBB to facilitate the entry of required nutrients into the brain and to exclude
potentially harmful compounds; however, this complex structure has remained
difficult to model faithfully in vitro. Accurate in vitro models are necessary for
understanding how the BBB forms and functions, as well as for evaluating drug
and toxin penetration across the barrier. Many previous models have failed to sup-
port all the cell types involved in the BBB formation and/or lacked the flow-
created shear forces needed for mature tight junction formation. To address these
issues and to help establish a more faithful in vitro model of the BBB, we have
designed and fabricated a microfluidic device that is comprised of both a vascular
chamber and a brain chamber separated by a porous membrane. This design allows
for cell-to-cell communication between endothelial cells, astrocytes, and pericytes
and independent perfusion of both compartments separated by the membrane. This
NeuroVascular Unit (NVU) represents approximately one-millionth of the human
brain, and hence, has sufficient cell mass to support a breadth of analytical meas-
urements. The NVU has been validated with both fluorescein isothiocyanate
(FITC)-dextran diffusion and transendothelial electrical resistance. The NVU has
enabled in vitro modeling of the BBB using all human cell types and sampling
effluent from both sides of the barrier.VC 2015 Author(s). All article content, except
where otherwise noted, is licensed under a Creative Commons Attribution 3.0
Unported License. [http://dx.doi.org/10.1063/1.4934713]
I. INTRODUCTION
The blood-brain barrier (BBB) is a critical structure acting as the gatekeeper between the cen-
tral nervous system (CNS) and the rest of the body. Not only does this unique barrier regulate
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traffic of small molecules, hormones, and nutrients between the body and the brain but it is also
the principal means of regulating drug and toxin access into the brain. Because of these features,
the ability to model the BBB is essential to testing the delivery and safety of drugs designed to act
in the CNS.
The BBB is also a complex structure comprised of multiple cell types, of which endothelial
cells have received the most attention. Tight junctions between endothelial cells form a physical
link and prevent the passage of molecules from the blood directly into the brain. It has been
shown that both cell-to-cell interactions and diffusible cues from the CNS, primarily originating
from pericytes and astrocytes, are necessary for cell polarity and the proper formation of tight
junctions.1,2 In addition to multiple cell types, true formation of a BBB requires shear forces
experienced by endothelial cells from blood circulation, as well as the differential serum con-
centration across the BBB.3,4 Thus, recapitulation of this complicated and dynamic barrier of
the BBB requires innovation for high fidelity modeling.
Current animal models, while informative, are expensive and have been shown to lack con-
sistent predictive value for humans.5–7 Recent research has shown that microvascular cells have
species-specific properties that may account for these differences between the human BBB and
those of other mammalian species. Current computer models of the BBB are excellent for high-
throughput studies and limit cost, but they are only useful for predicting basic permeability based
on drug structure—they cannot provide information as to the efficacy of the drug in question or
whether the drug itself may influence BBB permeability.8,9 Traditional transwell cell culture mod-
els have the advantage of being able to use actual human cells with relatively high throughput,
but it has been demonstrated that many of the cell types used in these experiments do not main-
tain their terminally differentiated state under these culture conditions, causing perturbations and
abnormalities within the BBB.6,10–13 Three-dimensional dynamic models overcome the differen-
tiation issues seen within transwells, but do not faithfully recapitulate the lumen and sub-lumen
spaces which allow for endothelial cell specialization14–18 and polarization.5,19,20 In addition,
these static models lack continually refreshed media.14,21–23 All of the current models add to our
understanding of the BBB formation and function; however, each still leaves room for improve-
ment to better represent this complex, multi-dimensional, multi-cellular brain structure.
The organ-on-chip community is expending significant effort on the development of advanced,
tissue-engineered microphysiological systems, typically using microfluidics.24–27 Planar microfluidic
BBB models are excellent for examining the BBB in cross-section, particularly to observe leukocyte
extravasation, but lack the cell number to support in-depth secretome characterization.28–31 To
address the limitations of the classic BBB models and extend the capabilities of planar microfluidic
ones, we have developed a self-contained microfluidic bioreactor that recreates the in vivo-like con-
ditions of the BBB in vitro. Our BBB organ-on-a-chip system, termed the NeuroVascular Unit
(NVU), supports growth and development of primary cell-derived human neurons, astrocytes,
pericytes, and microvascular endothelial cells, all of which are involved in the proper formation
of the BBB. The NVU not only allows these cells to differentiate and survive but also recreates
such important microenvironmental conditions as cell-to-fluid volume ratios, spatial gradients, and
proper fluid flows with appropriate shear stresses. We believe that our organ-on-a-chip NVU sys-
tem will enable bridging the gap between animal and human models of the BBB and help in
understanding how various assaults and manipulations can perturb the function of the BBB.
II. MATERIALS AND METHODS
A. NVU design
Our NVU (Figure 1(a)) is designed to be approximately one-millionth the size of an adult
human brain.32 The NVU is made up of three polydimethylsiloxane (PDMS) layers (Figure
1(b)) plus the 0.2 lm pore polycarbonate membrane that divides the two chambers. At present,
we use track-etched polycarbonate membranes, similar to those found in commercially available
transwells, to provide the scaffold for vascular cells and nervous system cells to grow in a two-
compartment arrangement. The membrane is bonded between layers of PDMS to create the
microfluidic vasculature and brain compartments (Figures 1(a) and 1(c)). The NVU has two
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perfusion streams, one for the vascular media supply to the endothelial cells in layer 1 (Figure
1(c), on bottom in red), with an inlet and outlet port, and another for the brain media supply to
layers 2 and 3 (in blue, Figure 1(c)), with four ports, so that one diagonal pair can be used for
collagen and cell loading and the other for subsequent perfusion of the brain compartment.
While not in use, these ports are closed with knotted tubing. The design of layer 3 was chosen
to facilitate even and uniform loading of collagen gel containing cells. The volumes of the vas-
cular and brain chambers are 2.91 ll and 17.5 ll, respectively. The two chambers share a com-
mon outline, eliminating problems that might arise in crossed-channel bioreactors wherein only
a portion of the two chambers overlap, creating larger populations of cells that do not share im-
portant signals.28,30 Because we need to grow cells on each side of the membrane, it is neces-
sary to perfuse the NVU device first with the vascular side of the membrane facing up to seed
the endothelial cells. Once the cells adhere to the membrane, the device can be turned over so
that the vascular side faces down, allowing the seeding of astrocytes and pericytes to the other
side of the membrane. It is always a challenge to invert transwell inserts for this purpose, but
for the NVU we designed a flippable backpack that maintains the feed and collection vials in
an upright position regardless of the orientation of the NVU device (Supplementary Figures
1(a) and 1(b)).69 This backpack enables culture of the NVU in either of its orientations while
still maintaining a standard 6-well footprint for ease of imaging (Figure 1(d)).
FIG. 1. Layout and design of the NeuroVascular Unit (NVU). (a) Schematic view of the NVU indicating major compo-
nents, cell types, and their spatial arrangement: endothelial cells lining the lower, vascular chamber; astrocytes and peri-
cytes lining the other side of the filter membrane, with neurons in the collagen gel in the upper brain chamber. (b)
Photolithographic masks used to fabricate the three-layered NVU. L in and L out—ports used for cell and extracellular ma-
trix (ECM) loading; P in and P out—ports used for perfusion. (c) A photograph of the assembled NVU loaded with colored
dyes indicating different compartments: red¼ vasculature; semi-transparent white¼filter membrane; turquoise¼ brain
compartment; blue ¼ brain perfusion. (d) NVU device with this perfusion system on an incubated microscope stage.
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B. NVU fabrication and assembly
We used standard soft-lithographic replica molding to create the three layers of PDMS that
comprise the NVU.33 The vascular layer and brain perfusion (or “H” layer, given its overall
shape) (Figure 1(b), layers 1 and 3, respectively) were produced by pouring PDMS onto a mold
created photolithographically with SU-8 2100 photoresist (MicroChem, Newton, MA, USA) on
Si wafers. The channel height was 100 lm. The final thicknesses of the cured PDMS for the
vascular layer and “H” layer were 1mm and 3mm, respectively. The brain compartment
(Figure 1(b), layer 2) was fabricated by curing PDMS sandwiched between two large polycar-
bonate plates separated by 500 lm spacers with a block that defined the layer 2 brain chamber.
This resulted in a PDMS membrane of uniform thickness and a well-defined brain culture
chamber that is 4.75mm long  6.2mm wide  0.5mm deep. For all steps, we used a standard
10:1 ratio mixture of PDMS (Dow Corning).
The following procedure was used to assemble the NVU. After the PDMS was poured onto
the Si/SU-8 molds, it was allowed to cure overnight at 65 C. All layers were then removed
from their molds, trimmed to size, washed with isopropanol, and dried with nitrogen gas. We
used a Harrick model PDC-001 plasma oven to activate the PDMS surface and irreversibly bond
layers to each other and the glass slide. First, the vascular layer 1 was plasma-treated and
bonded to a 50mm  75mm microscope glass slide with the chamber facing upward. Next,
four access ports in layer 3 were punched for 1.5mm OD Tygon tubing, and both layers 2 and 3
were bonded to each other. Then the polycarbonate filter membrane (Sigma CAT #111106) with
0.2lm pores was bonded to layers 2 and 3 with 5% solution of 3-aminopropyltriethoxysilane
(APTES, 99% Cat #440140, Sigma-Aldrich, St. Louis, MO, USA) using the protocol described
in Ref. 34. Once the filter membrane was bonded, two additional ports were punched through
layers 2 and 3 to create access to load and perfuse the endothelial cells in layer 1. Finally, both
layer 1, attached to a glass slide, and combined layers 2 and 3 with the APTES-treated filter
membrane were exposed to oxygen plasma again and bonded together, creating a sealed NVU
device. Immediately following assembly, while the surfaces were still hydrophilic, both compart-
ments of the NVU were loaded with deionized (DI) water. Care was taken not to trap any air
bubbles within the rectangular brain compartment. If any did get trapped, the devices were
placed under house vacuum until the bubbles were dissipated through the PDMS walls. All
NVU bioreactors were gamma sterilized and stored under water until use.
C. Cell loading and culture in microfluidic devices
Primary human brain-derived microvascular endothelial cells (hBMVEC) from Applied Cell
Biology (Kirkland, WA, USA) were maintained in endothelial basal medium (EBM)-2 (Lonza,
Basel, Switzerland) containing 5% fetal bovine serum (FBS) and their growth bullet kit; however,
penicillin streptomycin 1 was substituted for the gentamicin to prevent neuronal toxicity.
Pericytes and astrocytes from ScienCell (Carlsbad, CA, USA) and ATCC (Manassas, VA, USA),
respectively, both primary cells, were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) F-12%þ 10% FBS. All cells, except human neurons (described next), were maintained
in T-25 flasks under standard culture procedure35 until collected for seeding into the NVU.36–38
Human induced pluripotent stem cells (hiPSCs) from de-identified normal subjects were
generated and maintained as previously described.39,40 From these, human cortical glutamater-
gic neurons were differentiated in multi-well plates coated with Matrigel for 80–90 days by an
11-day dual-SMAD inhibition protocol to generate early PAX6-positive forebrain neuroprogeni-
tors, followed by a cortical glutamatergic neuron induction protocol, as previously described.
Immediately prior to seeding into the NVU, the resulting human glutamatergic neurons were
harvested using Accutase (Innovative Cell Technologies, Inc., San Diego, CA, USA).
Prior to cell seeding, NVU devices were first coated with laminin at 9.6lg/ml for 24 h at
37 C. On Day 0, the devices were washed three times with warm EBM-2 media to remove
unbound laminin, and hBMVECs were loaded into the vascular compartment at 1  106 cells/ml.
The NVU was then inverted and incubated at 37 C overnight to allow attachment of the
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endothelial cells to the porous membrane. On Day 1, still inverted, the NVU was connected to a
constant 2ll/min flow of EBM-2 media delivered by either a syringe or peristaltic pump and
maintained this way until Day 12. On Day 12, the device was placed right-side up, and astrocytes
at 2  106 cells/ml and pericytes at 1  106 cells/ml were mixed and loaded into the brain cham-
ber and maintained under flow for two days. On Day 14, hiPSC-derived neurons were suspended
within a collagen I matrix (Invitrogen) at 1  106 cells/ml, loaded into the brain chamber, and
allowed to solidify for 2 h before flow was restarted at 2ll/min. This complete device was cul-
tured for 3 days in the presence of Rho-associated coiled-coil kinase (ROCK) inhibitor (10lM,
Tocris) Y-27632 (Sigma-Aldrich, St. Louis, MO, USA) on the brain side to help the neurons sur-
vive. Y-27632 (inhibitor for p160-ROCK) markedly diminishes dissociation-induced anoikis
(detachment-induced apoptosis) of dissociated single hiPSCs.41 It has been shown that ROCK in-
hibitor also increases the survival rate during thawing and re-plating of dissociated hiPSC-derived
neural precursors and mature neurons and supports regrowth of neurites after injury.42–45 The pro-
cess of loading the neurons into the NVU requires their removal from the original culture dish in
which they were differentiated and their dissociation into single cells. Thus, ROCK-inhibitor
Y-27632 was added to the medium for the first 3 days after seeding the neurons into the NVU to
boost their survival. Once the ROCK inhibitor has been removed, the blood-brain barrier within
the NVU is considered mature because (1) tight junctions have formed, (2) all barrier cells are at
confluence, and (3) the neurons no longer need ROCK inhibition for survival. Finally, all cells
were perfused with EBM-2 media, and the device was ready for testing.
D. Establishing a cellular blood-brain barrier
To truly recapitulate the complexity of the BBB, we felt it imperative that its three major
cell types be present (endothelial cells, astrocytes, and pericytes), as well as neurons to evaluate
neuronal response to changes in BBB permeability. To this end we lined the vascular chamber
with HBMVECs (Figure 2(a)). The HBMVECs were given 12–14 days to reach confluence
(Figure 2(b)) and establish tight junctions. After the HBMVECs were established, the NVU was
then placed right-side up and a 2:1 mix of primary human astrocytes and pericytes (Figure
2(c)) was loaded into the brain chamber and given 1–2 days to reach confluence before seeding
with collagen gel containing 4  106 human neurons/ml differentiated from hiPSCs (Figure
2(d)). Once the cell seeding was completed and the four different cell cultures were established,
cell viability remained stable for all cell types between week 2 and 3, as determined by live/
dead analysis (>80% cell viability, Figures 2(a)–2(h)). Taken together, these findings demon-
strate that we can achieve a three-dimensional microenvironment capable of supporting multiple
cell types for long periods in culture without the loss of cell viability.
E. FITC-dextran diffusion across the BBB
Solutions of 10 KDa or 70 KDa fluorescein isothiocyanate (FITC)-dextran (Sigma-Aldrich, St.
Louis, MO, USA) were prepared at 1lm/ml (100nM for 10KDa and 700nM for 70KDa) in cell cul-
ture media. Then the vascular compartment of the NVU was perfused with either 70 or 10 KDa solu-
tion for 23 h. At the 23 h mark, the flows through both the vascular and brain compartments were
stopped for 1 h, allowing the dextran to diffuse across the BBB and accumulate in the brain compart-
ment. After a 1 h pause, perfusion of both chambers was restarted and individual effluents were col-
lected for fluorescent intensity analysis using a plate reader (TECAN M1000). By measuring FITC-
dextran diffusion across the membrane, we are able to evaluate the effectiveness of our BBB.46,47
F. Ascorbate transport across the BBB
Twenty-four hours before testing, the NVUs were switched into media containing no vita-
min C. At time 0, 100 lM ascorbate was added to the vascular media, and samples were col-
lected for both FITC-dextran analysis and ascorbate transport every 15min for 1 h. Perfusate
samples for ascorbate (20 ll) were treated with 20 ll of 25% metaphosphoric acid, mixed by
vortexing, and treated with 80 ll of 0.1M Na2HPO4 containing 0.05mM EDTA, pH 8.0. After
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vortexing briefly, the samples were centrifuged at 4 C for 1min at 13 000 g. The supernatant
was taken for assay of ascorbate by high performance liquid chromatography as previously
described.48
G. Cold shock and glutamate exposure
We used cold shock and exposure to glutamate to evaluate the quality of the BBB estab-
lished within the NVU and its physiological responses to chemical and environmental
FIG. 2. Live/dead stain of cell culture within the NVU. (a) Human brain-derived microvascular endothelial cells in the per-
fusion channel of the NVU. Live¼ green; dead¼ red (DIV 14; DIV¼ days in vivo). (b) Endothelial cells coating the vascu-
lar chamber (DIV 14). (c) Pericytes and astrocytes on the membrane in the brain chamber. (d) Neurons in the brain
chamber suspended in collagen gel (DIV 14). (e) Endothelial cells in the perfusion channels of the NVU (DIV 21). (f)
Live/dead and (g) live-only staining of endothelial cells coating the vascular chamber side of the membrane (DIV 21).
Over 80% viability is maintained after 3 weeks in culture (DIV 21, live only). (h) Pericytes and astrocytes on the brain side
of the same membrane region as in (g) and (h), with the collagen shrinkage shown.
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perturbations. For glutamate exposure, NVUs were first maintained under normal culture condi-
tions for 14 days to develop a mature BBB, then the media perfusing the vascular compartment
was switched to one containing 1mM of glutamate (Sigma-Aldrich, St. Louis, MO, USA) and
flowed through the reactor for 1 h. At the end of a 1 h exposure to glutamate, the state of the
BBB was evaluated using FITC-dextran as described above. For cold shock exposure, the
NVUs were cultured normally for 18 days and then were placed for 12 h at 33 C. The disrup-
tion of the BBB was evaluated as changes in transendothelial electrical resistance (TEER)
measured between the vascular compartment and the “H” layer.
H. TEER measurements in the NVU
TEER measurements were performed using our custom-built impedance analyzer based on
an AD5933 chip (Analog Devices, Nashua, NH, USA) and utilizing a four-probe approach.49
Electrical connections to the NVU chambers were created by incorporating 5mm long sections
of 23 ga stainless steel tubing into the media-supply Tygon tubing 2.5 cm away from the NVU
inlets (Supplementary Figure 2).69 While it might still suffer from the cable properties outlined
in Ref. 50 these measures did change as the biology of the cells changed, indicating its biologi-
cal relevance. The current source probes were connected between the inlet of the “H” layer and
the vascular chamber outlet, ensuring that the excitation current flowed across the brain com-
partment and through the endothelial layer. The sensing voltage probes were connected between
the vascular chamber inlet and the “H” layer outlet. Unlike commercially available TEER
instruments, such as the WPI Evom2, where impedance measurements are performed at a single
frequency of 12.5Hz, we have the ability to monitor impedance as a function of probe fre-
quency between 3 and 100 KHz, allowing us to determine the range of frequencies with the
highest sensitivity to cell-to-cell junction formation. Impedance measurements were taken once
a week with the full range frequency sweep.51 Changes of impedance at 15 kHz showed the
largest change as a function of BBB maturation.
I. Imaging and data analysis
Fluorescent images of the cells stained within the NVU were collected using a Zeiss
Axiovert 200 automated microscope equipped with a CoolSnap CCD camera. Collected images
were analyzed with ImageJ.
Tight junction evaluation was conducted as detailed in Ref. 12 using ZO-1 (Invitrogen)
directly conjugated to Alexa 488. In brief, greyscale measurements of the border between cells
were taken for 30 different cell-to-cell junctions and an average intensity was derived for each
culture condition.
Actin orientation assessment was conducted using phalloidin staining of actin fibers.52
Actin filaments were defined as a line longer than half the diameter of the cell in which they
were being measured. They were scored as being parallel with flow if their orientation had
fallen within 60 of the direction of flow (630), or perpendicular if they were within 60
(630) normal to the flow. The remaining actin fibers were classified as having orientation in-
dependent of the flow. Bundles were assigned a straight line vector for analysis.53,54 For a given
cell, 10 filaments were chosen at random for each cell counted.
For both tight junction and actin orientation, four fields of view for each bioreactor were
used for statistical analysis. Statistical analysis was performed using unpaired Student’s t test
for p values N> 8. For sample sizes of less than 8, the Mann-Whitney U test was performed to
generate p values.55
III. RESULTS AND DISCUSSION
A. Development of a multi-chambered perfusable microfluidic device
Current in vitro BBB models, such as the popular transwell-based cell culture method,56
are predominantly static, i.e., they lack flow and therefore also the shear forces needed
for mature barrier formation.56 These models also suffer from high media-to-cell volume
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ratios that dilute out important co-culture signals. By restricting flow to the microfluidic
chamber, BBB devices can provide the requisite flow velocities and shear forces to polarize
endothelial cells.29 In developing our NVU device, we attempted to incorporate the best ele-
ments of the transwell culture, e.g., ease of cell culture of multiple cell types, while also
reducing the media volume-to-cell ratio and introducing the shear force needed for the for-
mation of mature tight junctions. The reduction in media volume is critical to any studies
that will couple different organ chips to avoid dilution of metabolites and paracrine, auto-
crine, or endocrine signals, both to ensure that they are present at physiological levels and to
aid in their detection.57 An additional concern for cell biologists (and a challenge in building
a BBB) is the ability to easily and in a clean and sterile manner invert their culture devices.
As our NVU chip is self-contained, closed, and can operate in any orientation, we designed
a flippable backpack for the feed and waste media vials (Supplementary Figures 1(a) and
1(b)).69 Taken together, the current NVU has four crucial design features that help it to
model the BBB: (1) adjustable flow on both sides of the barrier, (2) low media-to-cell vol-
ume, (3) scaffolding to orient and support multiple cell types, and (4) easy adjustment of ori-
entation of the device.
B. Characterizing the blood brain barrier with the NVU
Once we had achieved stable cell viability within our NVU device over a 3-week time
period, the next challenge was to evaluate how effectively it generated the mature, tight junc-
tions critical to the BBB’s selective permeability. Previous culture methods for generating
in vitro BBBs often lacked either the shear forces necessary to maintain a polarized and dif-
ferentiated state within the endothelial cells,3,10,19 or the appropriate paracrine factors from
astrocytes and pericytes for stable and selective function of tight junctions. Experiments
using gravity-fed microfluidic chambers show that with the addition of flow, and exposure to
pericyte- or astrocyte-conditioned media, we can establish high levels of tight junction stain-
ing that are stable over the course of two weeks after the tight junctions have formed
(Figures 3(a)–3(d)). When ZO-1 staining was quantified using mean greyscale intensity at the
cell border of thirty different cell-to-cell interactions, we found that pericyte-conditioned
media significantly increased ZO-1 intensity (p¼ 0.002, N¼ 30) (Figure 3(e)). Astrocyte-
conditioned media trended toward an increase but was not statically significant due to vari-
ability (Supplementary Figure 3).69 It should be noted, however, that flow alone was suffi-
cient for tight junction staining to be visible. Further, all cultures required the presence of at
least 5% serum to maintain cell viability. These experiments suggest that our NVU device,
which combines both the shear force of flow and access to paracrine factors from pericytes
and astrocytes, is ideal for generating and maintaining tight junctions58–60 in brain-derived
endothelial cells.
In addition to markers for tight junction formation, another vital component for BBB for-
mation is polarization of the endothelial cells in the direction of flow.4,19,61 To evaluate cell po-
larity, actin filaments in endothelial cells under our various culture conditions were stained with
phalloidin. We then assessed the percent of actin filaments whose orientation was parallel to
the direction of flow. Filaments were considered to have an orientation parallel to flow if they
were within 32.5 (60 arc) of the flow vector (Figures 4(a)–4(d)). Control cultures under flow
show 65% of actin filaments orienting in the direction of flow. This number increased to 78%
with the addition of pericyte-conditioned media. Interestingly, astrocyte-conditioned media
encouraged polarization of actin filaments perpendicular to the direction of flow. Cells main-
tained in no-serum media showed little, if any, actin bundle formation at all (Figure 4(e)).
These findings demonstrate the need for flow, serum, and pericyte-generated factors for the for-
mation and orientation of actin filaments in the direction of flow in the development of a
mature BBB.
Having established that the necessary components for BBB formation are indeed present
and maintained in our NVU device, we then tested the function of this in vitro BBB. One of
the classical ways to evaluate the BBB function is the diffusion of sucrose molecules across the
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barrier. The smaller the molecule, the more easily it should diffuse through the gaps between
cells; however, a functional BBB significantly reduces the diffusion of even very small mole-
cules.2,7,61–63 To evaluate the effectiveness of our BBB, we tested the permeability of two dif-
ferent molecular weight fluorescent dextrans. The fluorescent dextran was diluted in the vascu-
lar side media feed, and effluent from both the vascular and the brain chambers was then
evaluated for the presence of fluorescence after 1 h diffusion and collection. FITC-dextran
diffusion tests showed that our NVU BBB significantly blocked both 70 kD and 10 kD FITC-
dextran from diffusing from the vascular chamber into the brain chamber (p¼ 0.01). We also
showed that disruption of the BBB by exposing it to 1mM glutamate, which is known to con-
siderably disrupt tight junctions, does indeed significantly increase diffusion of FITC-dextran
across the BBB (Figures 5(a)–5(c)). While both are significant effects, the first compares the
FIG. 3. ZO-1 staining of HBMVECs in microfluidic channels under flow and under different culture conditions. (a) Control
culture using EBM-2 media, showing higher intensity ZO-1 staining around the cell border that indicates tight junction
staining. (b) Astrocyte-conditioned EBM-2 media, showing a trend towards increased tight junctions. (c) Pericyte-
conditioned EBM-2 media, showing significant increases in staining around the cell border (p¼ 0.002, N¼ 10). (d) EBM-2
media with no serum, showing that the absence of serum reduces cell survival. (e) Mean intensity of ZO-1 staining at cell
borders. 10 cells for each condition were evaluated and could not share a border with a cell that had already been counted.
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cellular barrier only to the mechanical properties of the device, while the second is a biologi-
cally relevant disruption (but does not destroy the BBB such that the graphs in Figure 2 have
differing scales). In combination, these experiments demonstrate the generation of a functional
cellular barrier within our NVU.
Next, we next undertook to show that active transport—another critical component of the
BBB often overlooked in cellular BBB models46—could be shown in our system. To this end,
we used ascorbate, which is known both to tighten the BBB64 and be actively transported
across the barrier,65,66 as an indication of active transport. In looking at ascorbate concentration
over time, we saw a significant increase in all four NVUs tested (p¼ 0.01) (Figure 6(a)). In
contrast, FITC-dextran diffusion across the barrier was significantly reduced (p¼ 0.0012) by the
addition of ascorbate, and then remained steady over time (Figure 6(b)). Since diffusion cannot
account for the increase in ascorbate on the brain side, this is an indication of active transport.
In addition to testing fluorescent molecule diffusion to evaluate the effectiveness of our
in vitro BBB, we have developed a custom TEER measuring device specifically for the NVU to
FIG. 4. Actin staining of HBMVECs under flow and under different culture conditions. (a) Control culture with EBM-2
media, showing actin polarization with 65% of the actin filaments oriented in the direction of flow. (b) Astrocyte-
conditioned EBM-2 media, demonstrating actin polarization filaments oriented perpendicular to the direction of flow. (c)
Pericyte-conditioned EBM-2 media, showing actin polarization with 78% of the actin filaments oriented in the direction of
flow. (d) EBM-2 media with no serum, showing reduced cell survival and neither actin polarization nor actin bundle forma-
tion. (e) Percent of actin filaments that orient in the direction of flow. For each condition, 30 cells were evaluated for actin
bundle orientation.
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FIG. 5. FITC-dextran diffusion across the complete NVU BBB with all four cell types. (a) The concentration of 70 kD
FITC-dextran and (b) 10 kD dextran in the vascular chamber is significantly less than across the membrane in the brain
chamber (both p¼ 0.01, N¼ 6), as compared to the device whose cells were permeabilized with Triton. (c) Glutamate ex-
posure for 1 h significantly increases the concentration of 10 kD FITC-dextran across the membrane (p¼ 0.01, N¼ 6).
FIG. 6. Ascorbate transport across NVU. (a) The ascorbate concentration across the BBB for 4 separate NVU devices,
showing increases over time (p¼ 0.01). (b) 10 kD FITC-dextran diffusion across the BBB, showing no change
(15–60min). After the addition of ascorbate to the vascular side at time 0, time 0–15min shows a significant reduction in
diffusion (p¼ 0.0012, N¼ 4).
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evaluate resistance across the endothelial cell membrane (Supplementary Figure 2)69 at a range
of frequencies over the time course in which NVUs were in cell culture. As was seen with stain-
ing for tight junction markers, there is a significant increase in TEER around Day 12 of approxi-
mately 30% (p¼ 0.05) (Figure 7(a)). The percent increase is typical of reports for TEER and
tight junctions,51 although our values are higher, as the NVU itself has a high natural impedance.
This correlates well with the histology verifying tight junction formation (Figure 3). In addition
to detecting tight junction formation, TEER was also useful for evaluating cell viability. In devi-
ces in which perfusion was occluded by 50% at Day 14 in culture, TEER showed a large drop at
Day 21, which was later shown to correlate with cell survival (Figure 7(b)). When tight junctions
(but not cell survival) were impaired via cold shock of 33 C for 12 h, TEER decreased signifi-
cantly (p¼ 0.001) (Figure 7(c)). Furthermore, these measures of impedance show that the NVU
device acts as a capacitor, with its peak impedance between 15–20 kHz, and that we can use the
FIG. 7. TransEndothelial Electrical Resistance (TEER) measurement of barrier integrity in the NVU as an indication of
tight junction formation. (a) TEER shows a significant increase (30%, p¼ 0.05, N¼ 6) compared to before tight junction
formation at Day 2 and after Day 12. (b) TEER provides cell viability information within the device, as demonstrated by
the drop in both TEER (60%) and cell viability (p¼ 0.001, N¼ 6) when perfusion was occluded by 50% after Day 14. (c)
Cold shock of 33 C for 12 h reduces tight junctions significantly, as evidenced by TEER (p¼ 0.001, N¼ 6). (d) The output
of a prototype swept-frequency TEER instrument, showing significant increases in TEER for the NVU device over time for
a range of frequencies.
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shape of this capacitance to monitor the health of our devices over time (Figure 7(d)). These find-
ings demonstrate not only the reliability of our custom TEER device in our NVU but also show
that our BBB is functioning as expected with regard to its endothelial cell resistance.
IV. LIMITATIONS
One of the limitations of our approach was the use of PDMS to create the NVU, given the
propensity of hydrophobic molecules to adsorb to the PDMS.67,68 We are proceeding to develop
an NVU that is fabricated out of harder thermoplastics to avoid this problem.
The measurement of TEER in a transwell device benefits from the large volume of culture
media on both sides of the membrane, in that the conductivity of the media ensures that each
side of the membrane is an electrical isopotential, and hence, a four-probe TEER measurement
records the potential drop across the membrane. With microfluidic devices, the access imped-
ance of the media in the narrow channels can be significant, and the measurement of TEER
then corresponds to the measurement of the properties of a distributed electrical cable with a
short length constant. The TEER measurement is then most sensitive to the membrane proper-
ties closest to the current injection electrodes.50 While our TEER measurement demonstrates
the expected decrease in barrier permeability as the cells grow to confluence and form tight
junctions, the exact extent of the region of the barrier being quantified is as yet unknown. For
this reason, we believe that the FITC-dextran measurements may be more representative of the
barrier function over the entire membrane in this type of NVU.
V. CONCLUSION
Our NeuroVascular Unit is a novel organ-on-a-chip bioreactor that combines microfluidics
and three-dimensional cell culture to successfully recreate structure and behavior of the BBB
and is a substantial improvement for modeling the human BBB. This unique microfluidic de-
vice provides an environment for all cell types involved in BBB formation, the shear forces
necessary for barrier formation, and the paracrine factors needed for long-term stable differen-
tiation of the BBB. This device also provides the structures necessary for growing human neu-
rons, so that the effects of drugs on neuronal function can be evaluated in the context of a BBB
to account for drug permeability and effects on the BBB itself. The dual perfusion nature of
this device allows for manipulation of either side of the BBB, as well as differential delivery of
drugs and nutrients to either the vascular or the brain chamber. Taken together, these innova-
tions provide a novel platform for modeling of BBB function and testing of drug toxicity and
permeability with regard to the CNS.
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